ovarian neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
The present study was designed to evaluate the E2-independent effect of ERα/β on leptin-mediated cell invasion and cell proliferation in ovarian cancer.
|
31077012 |
2019 |
ovarian neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
The Evolution of Estrogen Receptor Signaling in the Progression of Endometriosis to Endometriosis-Associated Ovarian Cancer.
|
30302736 |
2018 |
ovarian neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Estrogen receptor (ER) positivity and progesterone receptor (PR) positivity were significant protective factors against subsequent BC and ovarian cancer.
|
29885789 |
2018 |
ovarian neoplasm
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
Our results indicate a correlation between the presence of ESR1 methylation and a better clinical outcome in HGSC patients.
|
29807696 |
2018 |
ovarian neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Ovarian cancer is a major gynaecological cancer with different subtypes and studies have suggested that estrogen receptor (ER) or progesterone receptor (PR) positivity are associated with better clinical outcomes.
|
29137401 |
2017 |
ovarian neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens.
|
28073843 |
2017 |
ovarian neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical significance of ER alpha, inhibin A, calretinin, and Ki67 expression in granulosa cell ovarian tumors.
|
29250651 |
2017 |
ovarian neoplasm
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Differential expression of estrogen receptor subtypes and variants in ovarian cancer: effects on cell invasion, proliferation and prognosis.
|
28859612 |
2017 |
ovarian neoplasm
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
This study uses primary cultures of mouse ovarian surface epithelium (OSE) to demonstrate that one possible mechanism by which estrogen accelerates the initiation of ovarian cancer is by up-regulation of microRNA-378 via the ESR1 pathway to result in the down-regulation of a tumour suppressor called Disabled-2 (Dab2).
|
29196616 |
2017 |
ovarian neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
We constructed polygenic risk scores (PRS) using BC and OC susceptibility SNPs identified through population-based GWAS: for BC (overall, estrogen receptor [ER]-positive, and ER-negative) and for OC.
|
28376175 |
2017 |
ovarian neoplasm
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Expression of ER (Hazard Ratio (HR) = 0.18, 95% confidence interval 0.08-0.42, <i>p</i> = 0.0002) and of PR (HR = 0.22, 95% confidence interval 0.10-0.53, <i>p</i> = 0.0011) were significantly associated with longer ovarian cancer specific survival adjusted for age, grade, treatment center, stage, and residual disease.
|
28264438 |
2017 |
ovarian neoplasm
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Conversely, estrogen receptor signaling downregulates miR-486-5p and upregulates OLFM4 expression, slowing the development and progression of ovarian cancer.
|
26871282 |
2016 |
ovarian neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Accordingly, immunohistochemical analysis of ERα-negative tissue specimens from HGSOC patients showed a significantly greater TAM infiltration in premenopausal compared to postmenopausal women.
|
26797759 |
2016 |
ovarian neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Inhibitory effects of aromatase inhibitor on estrogen receptor-alpha positive ovarian cancer in mice.
|
24410765 |
2014 |
ovarian neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Expression and clinical significance of estrogen-regulated long non-coding RNAs in estrogen receptor α-positive ovarian cancer progression.
|
24481591 |
2014 |
ovarian neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Thus, miR-206 may be a promising candidate for the endocrine therapy of ERα-positive ovarian cancer.
|
24604205 |
2014 |
ovarian neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
This growth promoting effect of OC cell growth was mediated by miR-26a inhibition of the posttranscription of ER-α.
|
24466274 |
2014 |
ovarian neoplasm
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Our results demonstrate that PES1 may play important role in the progression of ovarian cancer by inversely regulating the ERα and ERβ expression.
|
24376209 |
2013 |
ovarian neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
In the present study, estrogen receptor α (ERα)-negative/GPER-positive OVCAR5 ovarian cancer cell line was used to investigate the role of GPER in the migration and invasion of ovarian cancer.
|
23580092 |
2013 |
ovarian neoplasm
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Despite estrogen receptor (ER) expression in 67% of OVCAs, small anti-estrogen therapy trials have been disappointing and the benefit of hormonal therapy has not been systematically studied in large well-designed trials.
|
23402742 |
2013 |
ovarian neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
There was significant enrichment of ESR1 binding present in multiple datasets near genomic regions associated with breast cancer (7.45-fold, p = 0.001), height (2.45-fold, p = 0.002), multiple sclerosis (5.97-fold, p < 0.0002) and prostate cancer (4.47-fold, p = 0.0008), and suggestive evidence of ESR1 enrichment for regions associated with coronary artery disease, ovarian cancer, Parkinson's disease, polycystic ovarian syndrome and testicular cancer.
|
24171864 |
2013 |
ovarian neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
19p13.1 and ZNF365 are susceptibility loci for ovarian cancer and ER subtypes of breast cancer among BRCA1 and BRCA2 mutation carriers.
|
22351618 |
2012 |
ovarian neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Meanwhile, the at-risk A allele was positively related with the occurrence of mucinous ovarian cancer (OR = 3.48; 95% CI:1.15-6.83; P = 0.001), low degree of differentiation (OR = 1.87; 95% CI:1.03-3.47; P = 0.003), lymph node metastasis (OR = 1.69; 95% CI: 1.14-2.75; P = 0.010) and estrogen receptor positive (OR = 2.72; 95% CI: 1.38-4.81; P = 0.002).
|
23095717 |
2012 |
ovarian neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A SNP 19 kb downstream of ESR1 (rs2295190, G-to-T change) was associated with invasive ovarian cancer risk, with a per-T-allele odds ratio (OR) of 1.24 [95% confidence interval (CI), 1.06-1.44, P = 0.006]. rs2295190 is a nonsynonymous coding SNP in a neighboring gene called spectrin repeat containing, nuclear envelope 1 (SYNE1), which is involved in nuclear organization and structural integrity, function of the Golgi apparatus, and cytokinesis.
|
20056644 |
2010 |
ovarian neoplasm
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
To study a potential role of estrogen receptor-alpha gene amplification for estrogen receptor overexpression in ovarian cancer, a tumor tissue microarray containing 428 ovarian cancers was analyzed by fluorescence in situ hybridization for estrogen receptor-alpha gene amplification and immunohistochemistry for estrogen receptor expression.
|
18690166 |
2009 |